Advertisement
Advertisement
ATAI
AtaiBeckley Inc. Common Stock
4.53
USDSponsored
+0.12
+2.72%
May 29, 15:58 UTC -4
Closed
After-Market
4.53
0.00
-0.07%
ATAI Earnings Reports
Positive Surprise Ratio
ATAI beat 11 of 20 last estimates.
55%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.57K
/-$0.11
Implied change from Q1 26 (Revenue/ EPS)
-98.47%
/+37.50%
Implied change from Q2 25 (Revenue/ EPS)
-97.97%
/-21.43%
AtaiBeckley Inc. Common Stock earnings per share and revenue
On May 12, 2026, ATAI reported earnings of -0.08 USD per share (EPS) for Q1 26, beating the estimate of -0.10 USD, resulting in a 23.08% surprise. Revenue reached 954.00 thousand, compared to an expected 11.33 thousand, with a 8318.64% difference. The market reacted with a +2.72% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 14.57 thousand USD, implying an increase of 37.50% EPS, and decrease of -98.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were AtaiBeckley Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, AtaiBeckley Inc. Common Stock reported EPS of -$0.08, beating estimates by 23.08%, and revenue of $954.00K, 8318.64% above expectations.
How did the market react to AtaiBeckley Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 2.72%, changed from $4.04 before the earnings release to $4.15 the day after.
When is AtaiBeckley Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for AtaiBeckley Inc. Common Stock's next earnings report?
Based on 11
analysts, AtaiBeckley Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $14.57K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement